JP2021530453A5 - - Google Patents

Info

Publication number
JP2021530453A5
JP2021530453A5 JP2020571855A JP2020571855A JP2021530453A5 JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
pharmaceutical composition
stereoisomer
acceptable salt
Prior art date
Application number
JP2020571855A
Other languages
English (en)
Japanese (ja)
Other versions
JP7328263B2 (ja
JP2021530453A (ja
JPWO2020006233A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039509 external-priority patent/WO2020006233A1/en
Publication of JP2021530453A publication Critical patent/JP2021530453A/ja
Publication of JP2021530453A5 publication Critical patent/JP2021530453A5/ja
Publication of JPWO2020006233A5 publication Critical patent/JPWO2020006233A5/ja
Priority to JP2023126807A priority Critical patent/JP2023145694A/ja
Application granted granted Critical
Publication of JP7328263B2 publication Critical patent/JP7328263B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020571855A 2018-06-29 2019-06-27 免疫調節化合物 Active JP7328263B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126807A JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
US62/692,176 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126807A Division JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Publications (4)

Publication Number Publication Date
JP2021530453A JP2021530453A (ja) 2021-11-11
JP2021530453A5 true JP2021530453A5 (https=) 2022-07-05
JPWO2020006233A5 JPWO2020006233A5 (https=) 2022-07-05
JP7328263B2 JP7328263B2 (ja) 2023-08-16

Family

ID=68987232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571855A Active JP7328263B2 (ja) 2018-06-29 2019-06-27 免疫調節化合物
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126807A Pending JP2023145694A (ja) 2018-06-29 2023-08-03 免疫調節化合物

Country Status (8)

Country Link
US (1) US12234220B2 (https=)
EP (1) EP3814330A4 (https=)
JP (2) JP7328263B2 (https=)
KR (1) KR102834593B1 (https=)
CN (1) CN113166100A (https=)
AU (1) AU2019293235B2 (https=)
CA (1) CA3102212A1 (https=)
WO (1) WO2020006233A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
CA3102212A1 (en) * 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
AU2020392427B2 (en) * 2019-11-27 2024-03-07 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
JP7682181B2 (ja) 2019-12-18 2025-05-23 ノバルティス アーゲー 3-(5-メトキシ-1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
PY2243958A (es) 2021-06-03 2023-01-20 Novartis Ag Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
US11395820B2 (en) * 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
CN109790143A (zh) * 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
BR112019015484A2 (pt) * 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
CA3102212A1 (en) * 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Immunomodulatory compounds

Similar Documents

Publication Publication Date Title
JP2021530453A5 (https=)
JP2021530451A5 (https=)
JP2021191784A5 (https=)
JP2019094340A5 (https=)
WO2020150417A3 (en) Compounds and compositions for treating conditions associated with sting activity
EP4331677A3 (en) Methods of treating feline coronavirus infections
CN113748114A (zh) 一种喹唑啉化合物及其在医药上的应用
JP2016515561A5 (https=)
JP2020511467A5 (https=)
JP2020503891A5 (https=)
RU2017143776A (ru) Пролекарства альвоцидиба, имеющие повышенную биодоступность
JP2020097577A5 (https=)
JP2007051159A5 (https=)
JPWO2022002237A5 (https=)
JP2013509429A5 (https=)
JPWO2020006233A5 (https=)
JP2021535147A5 (https=)
JP2013522326A5 (https=)
JP2011527299A5 (https=)
JP2019520343A5 (https=)
JP2021530487A5 (https=)
RU2016136193A (ru) Аминокарбонилкарбаматные соединения
JP2021525752A5 (https=)
JP2019151627A5 (https=)
JP2014148552A5 (https=)